A carregar...
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF–expressing tumor cells
BACKGROUND: Glioma immunotherapy is an active area of clinical investigation. Glioma-associated immunosuppression remains an obstacle to efficacious immunotherapy, and combination approaches are likely necessary for durable success. OX40 is a member of the tumor necrosis factor receptor superfamily...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5761505/ https://ncbi.nlm.nih.gov/pubmed/29016879 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox125 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|